Zynerba Pharmaceuticals announces the publication of a paper entitled, "Role of the Endocannabinoid System in Fragile X Syndrome: Potential Mechanisms for Benefit From Cannabidiol Treatment," in the Journal of Neurodevelopmental Disorders. The review of evidence suggests a central role for the endocannabinoid system ECS in neuronal development and cognitive function and in the pathogenesis of Fragile X syndrome FXS , and the potential role of cannabidiol as a treatment for FXS. The article can be accessed online at the Journal of Neurodevelopmental Disorders at URL publication describes the potential of Zygel as a treatment for Fragile X syndrome based on the central role the endocannabinoid system plays in neuronal development and function," said Armando Anido, Chairman and Chief Executive Officer of Zynerba. "The proposed mechanisms of action of cannabidiol are supported by the results from our Phase 3 CONNECT-FX trial in patients with Fragile X syndrome with greater than or equal to 90% methylation of the FMR1 gene, benefited from treatment with Zygel. These findings bolster our confidence in the design of the ongoing, confirmatory, pivotal Phase 3 RECONNECT trial."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZYNE:
- Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
- Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
- Zynerba now expects topline results from RECONNECT trial in 1H24
- Zynerba announces long-term data from Phase 2 INSPIRE trial with Zygel
- Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology